As such, gene editing with CRISPR-Cas9 technology with the intent to silence the mHTT, while positively targeting BDNF expression, provides a dual-action in addressing the pathological sequelae of HD as an aetiological and synaptic approach. Here, BDNF is linked to Huntington disease.